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Chronic obstructive pulmonary disease (COPD) is a chronic lung disease that is thought to affect over one
million people in Great Britain. The main factor contributing to the development of COPD is tobacco
smoke. This paper presents a microsimulation model for the development of COPD, incorporating
population dynamics and trends in smoking. The model simulates a population longitudinally
throughout their lifetimes, providing projections of future COPD prevalence and evaluation of the effects
of changes in risk factor prevalence such as smoking. Sensitivity analysis provides information on the
most inﬂuential model parameters.
The model-predicted prevalence of COPD in 2040 was 17% in males over the age of 35 years (13%
amongst non-smokers and 22% amongst smokers), and a modest decline over the next 25 years due to
recent trends in smoking rates.
The simulation model provides us with valuable information on current and future trends in COPD in
Great Britain. It was developed primarily to enable easy extension to evaluate the effects of occupational
and environmental exposures on lung function and the prevalence of COPD and to allow evaluation of
interventions, such as introducing health surveillance or policy changes. As longitudinal studies for
investigating COPD are difﬁcult due to the lengthy follow-up time required and the potentially large
number of drop-outs, we anticipate that the model will provide a valuable tool for health impact
assessment. An extended model for occupational exposures is under development and will be presented
in a subsequent paper.
Crown Copyright © 2015 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic
lung disease characterised by airﬂow obstruction that is thought
to affect over a million people in Great Britain [1], costing the
National Health Service an estimated £800 million in direct
healthcare costs [2]. The clinical diagnosis is made using a com-
bination of symptoms and lung function as measured by
spirometry. However, for the majority of cases, COPD remains
clinically undiagnosed [2,3].
The main factor contributing to the development of COPD isvier Ltd. This is an open access artitobacco smoke, with smokers having greater declines in forced
expiratory volume in one second (FEV1) than non-smokers [4e8].
Certain types of environmental and occupational exposures have
also been found to contribute to excess decline in lung function and
COPD; exposure to coal mine dust and respirable crystalline silica
have been associated with excess lung function decline [9e12] and
increased risk of mortality from COPD [13].
Disease simulation models have been developed for COPD in
recent years for a variety of applications, several of which have been
Markov-type models, using the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) stages [14] as the discrete states
being simulated. Some of these models have evaluated the cost-
effectiveness of treatment interventions [15e20] and some stud-
ied the impact of smoking interventions [21,22]. In particular, one
such model is a dynamic population model of disease progressioncle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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made of the future burden, as well as the evaluation of the impact
on future prevalence of different smoking cessation interventions
on the illness [19,22]. None of these models, however, consider the
impact of occupational or environmental exposures.
This paper presents a stochastic microsimulation model for the
development and progression of COPD, in discrete time steps of one
year, via continuous changes in forced expiratory volume in one
second (FEV1) and forced vital capacity (FVC). It enables the pro-
jection of the future burden of COPD, evaluation of the impact of
future changes in smoking trends, and the impact of interventions
that aim to reduce smoking.
2. Methods
2.1. Model structure
A microsimulation model was developed to simulate certain
attributes (e.g. gender, height) of each individual in the population,
updating their lung function in discrete time steps of one year. The
model comprises:
 A population model, describing the attributes and dynamics of
the population;
 A smoking model, representing demographic and individual
trends in smoking; and
 A disease model, characterising FEV1 and FVC and thus COPD
stage.
In the ﬁrst simulation year, an initial population of 20 year olds
was generated, based on input data that described the attributes of
the initial cohort. Appropriate spirometric reference equations
were then utilised to simulate FEV1 and FVC, incorporating
between-person variability in lung function. In every subsequent
simulation year, the existing cohort aged by one year, and each
individual's FEV1 and FVC was updated by applying annual declines
in FEV1 and FVC based on the individual's attributes in that year. In
each year, an individual's COPD severity status was determined
using the GOLD criteria (FEV1/FVC < 0.7, and GOLD stage deter-
mined by FEV1% predicted). New cohorts enter the population in
every year and their attributes are simulated. In addition, mortality
rates were applied to remove certain individuals from the popu-
lation, based upon age, birth year, gender, smoking status and COPD
severity, although their sets of attributes remained stored to enable
extraction at the end of the simulation.
2.2. Initial lung function and subsequent decline
The model was developed so that the user could select from a
choice of spirometric reference equations for simulating FEV1 and
FVC, including the European Coal And Steel Community (ECSC)
[23] and those based on the Health Survey for England 1995/1996
[24]. Initial FEV1 at entry into the simulation was assumed to be
highly correlated with FVC, as studies have shown [25]. As several
of the reference equations were based on data from “healthy”
individuals and excluded those with reported diagnosis of asthma
and respiratory symptoms [24] who generally have lower lung
function than the “healthy” population [26], adjustments to FEV1
and FVC had to be made. In terms of initial FEV1 and FVC, no
difference between asthmatics and non-asthmatics was assumed
(informed by analysis of data from the Health Survey for England
2001 [27]).
Lung function was assumed to decline over time, with the total
decline comprising components due to ageing (which is dependent
on the age, height and gender of the individual), smoking andasthma status. Each component was assumed to vary between in-
dividuals according to a lognormal distribution. The variation in
initial lung function and subsequent declines was implemented by
assigning all individuals four standardised random effects associ-
ated with initial FEV1, initial FVC, FEV1 decline and FVC decline. The
ﬁrst two random effects were assumed to be highly correlated with
each other, as were the last two. That is, individuals with large
initial FEV1 were assumed to have large initial FVC, and those who
were susceptible to large FEV1 declines were assumed to be sus-
ceptible to large FVC declines.
The random effects were assigned at entry into the simulation
and remained with them throughout the simulation period. That is,
once a susceptible individual entered the population, that indi-
vidual remained susceptible throughout their lifetime within the
simulation timeframe. The random effects were then scaled ac-
cording to the variance components for annual FEV1 and FVC de-
clines associated with age, smoking and asthma. Thus smokers
with relatively large age-related declines (after adjusting for
height) would also have had relatively large smoking-related de-
clines. Further details on the random effects and characterisation of
variability can be found in the Appendix.
The model inputs associated with FEV1 and FVC declines were
the mean annual FEV1 and FVC declines due to smoking status,
asthma, and their associated coefﬁcients of variation that charac-
terised the between-person variability in these declines. The mean
age-related declines were derived at the start of the simulation and
were based on the set of reference equations selected by the user.
The mean excess FEV1 declines in light and heavy smokers (deﬁned
as those consuming fewer than 24 cigarettes and 25þ cigarettes a
day respectively) were set to the declines found in moderate and
heavy smokers in a Dutch study with a 24 year follow-up [6] of
9.5 ml/year and 13.5 ml/year respectively. These ﬁgures were
comparable to the excess declines of 8 ml/year and 12 ml/year
found in those who smoked <20 and 20þ cigarettes a day in the
Honolulu Heart Program [28], 11 ml/year seen in a longitudinal
study in Busselton, Western Australia [5] and 12.2 ml/year from a
longitudinal analysis of ventilator capacity in The Copenhagen City
Heart Study [26].
The Dutch study [6] did not present FVC declines that were
required for the model. However [26] did present both FEV1 and
FVC declines but did not stratify by cigarette consumption; they
found the excess decline in FVC to be about 90% of the decline in
FEV1 (11 ml vs 12.2 ml). We applied this ratio to the estimates from
the Dutch study, in order to derive FVC declines of 8.6 ml/year and
12.2 ml/year as inputs to the model.
In the Dutch study [6], no signiﬁcant difference was found be-
tween lifetime male non-smokers (mean age 32 years) and former
male smokers (mean age 45 years) in terms of FEV1 decline,
therefore no excess declines were assumed for male ex-smokers in
the simulation model. The same study found an excess decline
of 4.4 ml/year in former female smokers, which is the value used
by themodel for females. The mean annual excess declines for FEV1
and FVC in asthmatics were set to 11.6 and 7.7 ml/year respectively
[26].
2.3. Demographics
The attributes that were simulated within the population
component were those on which absolute values of FEV1, FVC and
their declines have been found to be dependent (besides age),
namely gender [24], height [24] and whether the individual was
asthmatic [26]. Smoking status, another risk factor for excess lung
function declines, is simulated within the smoking model and is
described under the ‘Smoking model’ section.
For application of the model to Great Britain (GB), historical
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were obtained from the Ofﬁce for National Statistics [29]. Based
upon the proportion of males in the Health Survey for England
2001 reporting ever being told by a doctor that they had asthma
(The Health and Social Care Information Centre), it was assumed
that 15% of the GB population were asthmatic. Once individuals
entered the model as asthmatics, they remained asthmatic
throughout the simulation.
The model was set up such that the individuals in each new
cohort entered the simulation at age 20 and the attributes (gender,
height, asthma status and smoking status) of each individual were
randomly generated, based on the GB population.
In the ﬁrst year, and in each subsequent year, of the simulation,
the size of the added cohort of 20-year olds was proportional to the
actual number of 20-year olds in GB in that year. As the simulation
moved forward in time, the simulated population began to
resemble the true male adult population of GB. However the
simulation has to run for at least 60 years before the population
comprises individuals aged 80 years and over. Historical and future
mortality rates by gender, age and birth year were obtained from
the Ofﬁce for National Statistics [29]. For smokers, and those with
COPD, their mortality rate in a particular year was multiplied by the
appropriate risk ratios associated with smoking [31] and COPD [32]
respectively. Migration, both inbound and outbound, was not
included in the model.2.4. Smoking model
A Markov model was used to describe smoking cessation and
relapse in each individual (Fig. 1). It was assumed that non-smokers
entering the simulation remain non-smokers for the remainder of
their lives. Current smokers (categorised into light and heavy
smoking categories) were permitted to stop smoking to become ex-
smokers; ex-smokers were subsequently allowed to restart smok-
ing. Data on historical GB smoking prevalence were obtained from
The Ofﬁce for National Statistics [30]. The cessation rate, assumed
to be the same across all age groups and for the years 2007 onwards
(after the smoking ban in England came into force), was set to 4.8%,
which is the percentage of smokers in the Smoking Toolkit Study
who smoked in the past 12 months prior to 2010 but reported not
smoking in 2010 [33]. The cessation rate prior to 2007 was set to
half of the 2007 rate, as research [34] suggested a cessation rate in
2004 of between 2 and 3%.
The restart rate during the ﬁrst year of abstinence (15%) was
sourced from a recent study on long-term smoking relapse in theFig. 1. Schematic of smoking model.British Household Panel Survey [35]. For model simplicity, it was
assumed that once a smoker had quit for two or more years, they
remained ex-smoker for the remainder of their lifetime; based on
the same study [35], the restart rate during the second year of
abstinence within the model was also set to 15% to account for this
assumption.
2.5. Variance-based sensitivity analysis
The simulation model contained a large number of input pa-
rameters and the inﬂuence of some of these parameters on the
model outputs was not transparent. A sensitivity analysis can help
identify the parameters that are most inﬂuential for speciﬁc model
outputs and assess the robustness of the model-predicted preva-
lence of COPD to changes in parameter values. In this paper, a
variance-based sensitivity analysis is carried out, whereby the total
variance in the output is apportioned to the sources of variation in
the model inputs, thus enabling identiﬁcation of the most inﬂu-
ential model parameters. Although there were several different
outputs that may be evaluated following running of the simulation,
the focus of the sensitivity analysis was on the prevalence of COPD
(GOLD I to IV) in non-smokers and smokers at age 35, 45, 55 and 65
years. More details on the sensitivity analysis can be found in the
Appendix.
2.6. Implementation
Themodel was implemented inMATLAB [36] and run from 1961
to 2040 for a GB scenario with a total population size of 1.5 million
males (large enough that there was minimal variation due to
population stochasticity between model runs). For simplicity and
ease of demonstrating the model, females have not been simulated
in this paper. However females can be included in the model with
relative ease as the model incorporates female-speciﬁc reference
equations, smoking rates and mortality rates.
The spirometric reference equations selected for use in the
simulation were those based on the Health Survey for England
1995/1996 [24], which are appropriate for simulating a GB popu-
lation. Table 1 presents a list of the parameter inputs used in the
model and the associated data sources. The model provides data on
all simulated individuals such as their smoking history and COPD
severity stage in each year, allowing the population prevalence of
smoking and COPD to be calculated. In addition, a variety of other
individual-level outputs such as absolute FEV1 and FVC, annual
declines in FEV1 and FVC (stratiﬁed by risk factor group) and
population-level outputs such as annual incidence of COPD may be
determined.
Data presented in this paper reﬂect a ﬁrst application of the
model, to predict the current and future smoking prevalence in the
GB population by age group under the ‘baseline scenario’. It was
assumed that current trends in smoking prevalence amongst 20
year olds was maintained, i.e. a reduction of 0.5% per year as
derived from national prevalence data [30], whilst ignoring
migration and temporal trends in environmental and occupational
exposures that may also inﬂuence national prevalence of COPD.
Although the model uses smoking prevalence data in the 20e24
age group as inputs, it did not use data for the older age groups,
instead relying on the smoking cessation and relapse rates tomimic
smoking trends in GB across all ages. A second application of the
model was to predict the likely future prevalence of COPD in males
in GB under the ‘alternative scenario’, where the future cessation
rate was assumed to double.
The sensitivity analysis was then carried out in two stages, the
ﬁrst focusing on the inﬂuence of the input parameters on COPD
prevalence in non-smokers, and the second focusing on the
Table 1
List of model parameters, their input values and data source.
Parameter Value Data source
Proportion asthmatic 0.15 [27]
Asthma adjustment to baseline FEV1 (ml) 0 [27]
Asthma adjustment to baseline FVC (ml) 0 [27]
Asthma adjustment to FEV1 decline (ml) 11.6 [26]
Asthma adjustment to FVC decline (ml) 7.7 [26]
Excess FEV1 decline, light smoker (ml) 9.5 [6]
Excess FEV1 decline, heavy smoker (ml) 13.5 [6]
Excess FVC decline, light smoker (ml) 8.6 Informed by Refs. [6,26]
Excess FVC decline, heavy smoker (ml) 12.2 Informed by Refs. [6,26]
Coefﬁcient of variation for baseline FEV1 0.13 [27]
Coefﬁcient of variation for baseline FVC 0.13 [27]
Coefﬁcient of variation for age-related FEV1 decline 0.4 Expert judgement
Coefﬁcient of variation for smoking-related FEV1 decline 0.2 Expert judgement
Coefﬁcient of variation for asthma-related FEV1 decline 1 Expert judgement
Coefﬁcient of variation for age-related FVC decline 0.2 Expert judgement
Coefﬁcient of variation for smoking-related FVC decline 0.5 Expert judgement
Coefﬁcient of variation for asthma-related FVC decline 1 Expert judgement
Random effects correlation coefﬁcients:
Baseline FEV1, FEV1 decline 0.4 Expert judgement
Baseline FEV1, baseline FVC 0.88 Expert judgement
Baseline FEV1, FVC decline 0.4 Expert judgement
FEV1 decline, FVC decline 0.4 Expert judgement
FEV1 decline, FVC decline 0.9 Expert judgement
Baseline FVC, FVC decline 0.4 Expert judgement
Mortality risk ratio, light smoker 1.31 [31]
Mortality risk ratio, heavy smoker 1.79 [31]
Mortality risk ratio, ex-smoker 2.61 [31]
Risk ratio, GOLD II 1.41 [32]
Risk ratio, GOLD III 2.42 [32]
Risk ratio, GOLD IV 3.57 [32]
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within a 400-point Latin hypercube design matrix, maximising the
minimum distance between points. These 16 parameters and their
ranges used in the design matrix are presented in Table A1 in the
Appendix.
The simulation model was run at each of these design points
starting in 1961 for a single cohort of 500,000 males. For the latter
stage, an additional seven parameters associated with smoking
were considered (Table A2 in the Appendix). The inﬂuence of the
parameters on COPD prevalence in non-smokers and smokers at
ages 35, 45, 55 and 65 (i.e. in years 1976,1986,1996 and 2006) were
investigated. For each parameter, the main effect variance (the
percentage of the total variance due to just the individual param-
eter) and the total effect variance (the percentage of the total
variance due to the main effect of the parameter and its interaction
with other parameters) were calculated.
3. Results
Fig. 2 shows the historical and future smoking prevalence in
males in Britain as simulated by the model, for the age groups for
which national smoking prevalence data were available (ONS). As
the earliest year from which simulation could start is 1961 due to
availability of population data, the simulated population did not
include 25 year olds until at least 1966 and 50 year olds until 1991.
The model provided adequate predictions of smoking prevalence in
the general population over the simulation timeframe, mimicking
general trends. A local peak was seen in the 25e34 age group
around the year 2000, which may be explained in part by the
establishment of the NSH Stop Smoking Services in England and
Wales in 2000. This peak could not be reproduced by the model in
its current form; nevertheless the rates observed within the last
few years closelymatch the projected rates of this model. Under the
alternative smoking scenario, the impact of doubling smoking
cessation was, as expected, to decrease smoking prevalence. Thedifference was more noticeable in the older age groups, where the
prevalence under the two scenarios diverged due to the proportion
of smokers having quit increasing with increasing age. The alter-
native smoking scenario led to a halving of smoking rates within
the 50e59 year age group by the year 2040. Although this alter-
native smoking scenario may not necessarily represent a realistic
future trend in national smoking cessation rates, its intention was
to represent a hypothetical example of application of the model to
future interventions aimed at reducing smoking.
The model-predicted prevalence of COPD in 2014 (by smoking
status) was 9%, 18% and 15% in never smokers, smokers (light and
heavy) and ex-smokers between the ages of 35 and 73 years of age
respectively. These prevalence ﬁgures are comparable to those
based on a study of COPD in adults over 35 years of age in the
Health Survey for England 2001 [37], where the prevalence of COPD
(across both genders) was found to be 8.7%, 19.3% and 15.2%
amongst never smokers, smokers and ex-smokers respectively, and
in the Health Survey for England 2010 [38] with prevalence in
males over 35 years of 6%, 21% and 15% respectively.
The model-predicted prevalence of COPD in 2040 was 17% over
the age of 35 years (13% amongst non-smokers and 22% amongst
smokers); a modest decline was predicted over the next 25 years
prior to 2040 due to recent trends in smoking participation rates.
Fig. 3 shows the projected prevalence of COPD in males aged be-
tween 20 and 80 years in the year 2040. The overall COPD preva-
lence was predicted to be greater in current smokers (light and
heavy smokers combined) than never smokers. Across all ages, the
majority of COPD cases were GOLD I and II. However, a greater
proportion progressed to GOLD III/IV with increasing age especially
amongst smokers. By age 70 years, over a third of smokers were
predicted to develop COPD, with approximately a third of these in
the highest severity categories (GOLD III or IV).
Fig. 4 presents the distributions of FEV1 decline in male heavy
smokers and non-smokers at age 40, as simulated by the model.
The variation in declines amongst smokers was greater, due to
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Fig. 2. Model-predicted smoking prevalence in males by age group under the baseline (current smoking trends maintained) and alternative smoking scenario (doubling of cessation
rate after 2017).
E. Tan et al. / Respiratory Medicine 109 (2015) 1521e1531 1525variation induced by smoking as well as variation from ageing. Very
few experienced declines of less than 10 ml/year. At the upper end
of the distributions, few non-smokers and smokers had decline
greater than 60 and 100 ml/year respectively.
The results of the sensitivity analysis can be found in Tables A1
and A2 in the Appendix. The greater the variance contribution of a
parameter, the more inﬂuential that parameter and its interactions
were on COPD prevalence. The results indicate that amongst non-
smokers, the correlation between the random effects for baseline
FEV1 and baseline FVC was the most inﬂuential parameter for the50 40 30 20 10 0 10 20 30 40 50
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Fig. 3. Model-predicted COPD prevalence for male non-smokers and current smokers
(light and heavy smokers combined) in GB in 2040 by severity stage, assuming that
current smoking trends are maintained.COPD prevalence in younger adults. This parameter and its in-
teractions explained 41% and 29% of the total variation at ages 35
and 45 respectively. The coefﬁcient of variation of baseline FEV1
was also inﬂuential at these ages, explaining 31% and 29% of the
total variation respectively; this input and associated uncertainty
range were obtained from analysis of spirometric measurements
from the Health Survey for England, 2001 [27]. Amongst 55 and 65
year olds, the coefﬁcient of variation of the age-related FEV1 andFig. 4. Probability distribution of annual FEV1 decline in 40 year old males by smoking
status (NS ¼ non-smoker, S ¼ heavy smoker).
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between 18% and 47% of the total variation respectively.
Amongst younger adult smokers, the correlation between the
random effects for baseline FEV1 and baseline FVC was most
inﬂuential, explaining 28% of the total variation in COPD prevalence
at age 35. The mean smoking-related FEV1 decline was also highly
inﬂuential, explaining between 24% and 51% of the total variation
amongst all age groups. The model inputs and associated uncer-
tainty ranges for the declines were sourced from international
literature [6]; hence there is relatively high conﬁdence in themodel
inputs and associated uncertainty. The results of the sensitivity
analysis are presented in Table A1 and A2 in the Appendix, for non-
smokers and smokers respectively.
3.1. Validation
Validation is an important aspect of model development,
ensuring that the model provides robust forecasts of health out-
comes under various scenarios. Obstructive lung disease models
and their validity have been reviewed [39]; four types of model
validation were deﬁned for the purpose of the review. The aim
within the current model development was to achieve at least
third-order validation. First-order validation, deﬁned as the process
by which the model structure is examined for coding errors, logical
inconsistency, and accuracy of mathematical calculations, has been
carried out by having a second modeller examine the code for
coding errors, both modellers examining the outputs of the model
and verifying their plausibility (such as FEV1 and FVC lying within
plausible ranges and declining over time). Second order validation,
deﬁned as comparison of model predictionswith existing data from
studies that were used to parameterize, construct, or develop the
model, was carried out by comparing the mean of the model-
predicted FEV1 and FVC for non-smokers at various ages with
those predicted by the FEV1 and FVC reference equations used in
the model. These values were found to be very similar. A compar-
ison for smokers was not attempted as the reference equations
were based on spirometric measurements of a population that
excluded smokers and ex-smokers. In addition, it was shown there
was good agreement between the predicted prevalence of smoking
in 25þ year olds and the ONS smoking data [30].
Third order validation, deﬁned as comparison of model esti-
mates with published data from studies that were not used to
parameterize, construct or develop the model, was then carried out
by comparing the model-simulated FEV1/FVC ratios with those
from the Health Survey for England, 2010 (HSE 2010) [38]. The
median values of FEV1/FVC for white males aged 35e45, 45e55 and
55e65 years from the HSE 2010were 0.79 (5th and 95th percentiles
0.68e0.87), 0.78 (0.66e0.85) and 0.76 (0.62e0.84), comparable to
the model-simulated values for white males of 0.80 (0.69e0.91),
0.78 (0.66e0.90) and 0.77 (0.64e0.91). In addition, the coefﬁcient
of variation of FEV1 and FVC produced by the model at various age
groups were comparable to those from the HSE 2010 (the coefﬁ-
cient of variation increasing with age), providing additional reas-
surance of the validity of these model components.
4. Discussion
The model presented in this paper has been applied to the gen-
eral male population of GB to provide projections of future smoking
prevalence aswell as the future burden of COPD, providing adequate
predictions of smoking prevalence in the general population over
the simulation timeframe and mimicking general trends. Applica-
tion of the model to alternative populations, including females, may
be carried out with relative ease by substituting the GB-speciﬁc
demographic data and smoking prevalence rates with those forthe speciﬁc population of interest. It should be noted, however, that
the spirometric reference equations used in this study to simulate
FEV1 and FVC, and that are currently incorporated in the simulation
modelwere based onwhite Caucasian adults. Thus their usemay not
be appropriate for populations with mixed ethnicity. Alternative
reference equations such as those based on the third National Health
and Nutrition Examination Survey (NHANES III) [40] for African-
American and Mexican-American populations, and the GLI-2012
set of equations [41] for North East Asian and South East Asian
populations may easily be accommodated. Currently the model in-
cludes four choices of spirometric reference equations (for males
and females) for use in simulating lung function; the ECSC, GLI-2012,
NHANES III and those based on the HSE [24], with the choice being
given to the user.
The development and progression of COPD was modelled via
changes in FEV1 and FVC on the continuous scale, allowing for
continuous distinctions in lung function between risk factor
groups. The model was set up such that every individual enters the
simulated population aged 20 years. The reason for this is that lung
function increases during childhood and is thought to peak or reach
a plateau during early adulthood [42]. Rather than attempt to
model the potentially complex pattern of lung function in those
aged below 20 years, where there are very few cases of COPD, the
simulation included only those aged 20 years and above. The effects
of teenage smoking prior to age 20 have been ignored due to the
difﬁculty in simulating smoking habits in young adults and the lack
of relevant data for this age group.
The model assumes that the excess decline in lung function in
an individual is independent of the presence of COPD. However, as a
greater proportion of the ‘susceptible’ individuals (i.e. those with
greater than average annual declines) are likely to develop COPD
than the rest of the population, and as these individuals will remain
susceptible throughout their lifetimes, greater excess declines in
the presence of COPD is implicit.
Under the alternative smoking scenario where smoking cessa-
tion doubled, lower subsequent smoking rates were seen in com-
parison to the baseline scenario with the differences being more
apparent in the older age groups. The model provided data on the
simulated annual declines which could be beneﬁcial for comparing
the variation in annual declines by risk factor groups.
The model-predicted COPD prevalence rates, by smoking status
and age group, have been comparedwith those based on the Health
Survey for England 2001 (HSE 2001) [27] and 2010 (HSE 2010) [38]
and found to be comparable. As additional validation steps, the
model-predicted coefﬁcient of variation of FEV1 and FVC within
various age groups were also found to be comparable to those from
the HSE surveys. As data from the HSE 2010 survey was not used to
develop the model, the comparison provides veriﬁcation that the
simulation model results are plausible and consistent with actual
data that did not contribute to model development.
The model inputs and uncertainty distributions for the most
inﬂuential parameters in young adults were obtained from analysis
of the Health Survey for England 2001 [27], which provided lung
function data for almost 20,000 individuals in England; the inputs
are therefore considered to be obtained from a reliable source.
Although the COPD model aims to simulate lung function, the
model is, to a certain extent, a simpliﬁcation of reality. It is unfea-
sible to incorporate every relevant parameter and assumptions are
therefore unavoidable. Information on all elements of inter-
individual variation in lung function was not available and some
expert judgements were necessary to provide the necessary inputs
into the simulation model. However, the sensitivity analysis sug-
gests that those elements of variationwere generally not inﬂuential
for the COPD prevalence outputs.
An advantage of the disease modelling approach presented in
E. Tan et al. / Respiratory Medicine 109 (2015) 1521e1531 1527this paper is that it does not rely on estimates of the incidence of
COPD and extrapolation of historical trends in COPD incidence or
prevalence in order to predict future disease burden. This allows
application of the model to other countries where population-level
information on COPD is unavailable or less reliable. It is worth
noting that although the model can follow a cohort over time, it is
not limited to modelling a cohort and an advantage is that it can
follow individuals entering themodel at various time points, within
the simulation timespan.
Computer simulationmodels for long-latency diseases have been
popular in recent years due to their wide range of potential appli-
cations. For COPD, simulation models allow the evaluation of the
impact of changing smoking habits within a population, or the
comparison of different treatments for COPD. One such model is a
dynamic population model of disease progression in Dutch patients
with diagnosed COPD, allowing projections to be made of the future
burden of COPD in The Netherlands, as well as the evaluation of the
long-term impact of different smoking cessation interventions on
national COPD prevalence [19,22]. A recent study [43] compared
different COPD cost-effectiveness models with respect to structure
and input parameters. Like those models, our COPD simulation
model uses the GOLD classiﬁcation, however at a conceptual level,
there are several differences. For example, our model is a micro-
simulation model that simulates both FEV1 and FVC annually, which
both then determine whether the individual develops COPD or
progresses to the next GOLD stage. In addition, our model is able to
capture heterogeneity of lung function between individuals via the
random effects. In comparison, most other COPD models do not
simulate absolute values of lung function, instead using transition
probabilities (some of which are speciﬁed by age, smoking status
and disease severity) to simulate movement of individuals between
COPD states [15,44]. Unlike most other models, we have not
modelled the frequency of exacerbations, however the intention is
to eventually incorporate this aspect.
The simulation model presented in this paper allows an
assessment of the impact of smoking cessation interventions,
changing trends in smoking, or changing demographics. However,
the primary aim of the work was to develop a model for COPD that
can subsequently be adapted to take into account other inﬂuences
on long function decline, including occupational and environ-
mental exposures, and genetic effects, in order to inform policy-
makers and healthcare providers. Such extensions should be rela-
tively straightforward as long as the required dose responses (e.g.
declines in FEV1 and FVC per unit of exposure) are available. For this
reason, a more comprehensive evaluation of the impact of smoking
interventions has not been presented in this paper. As longitudinal
studies for investigating occupationally-related COPD are difﬁcult
due to the lengthy follow-up time required and the potentially large
number of drop-outs, the extended model for occupational expo-
sures will provide a valuable tool for health impact assessment. The
extension and application of the model to occupational exposures
are currently under development will be presented in a subsequent
paper.
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Characterising lung function variability.
The COPD disease model simulates every individual's lung
function from the age of 20 years. For this step, the mean FEV1 and
FVC at age 20 are determined using a user-speciﬁed spirometric
reference equation. As most reference equations include height as a
covariate, the mean FEV1 and FVC are likely to vary with height of
the individual. Then, for each individual, the means are scaled by a
lognormally distributed random effect. For individual i, this corre-
sponds to FEV1 and FVC at age 20 of:
FEVi ¼ emFEV ai11y1
FVCi ¼ emFVCai12y2
where mFEV and mFVC are the means of the underlying normal
distribution of initial FEV1 and FVC respectively, ai11 and ai12 are
normally distributed random effects with mean 0 and variance 1
and n1 and n2 are the standard deviations of the underlying normal
distribution for FEV1 and FVC at age 20 respectively. In each year of
the simulation, lognormally distributed annual declines related to
age, smoking and asthma are applied to the previous year's lung
function, i.e. lung function in year t is calculated by subtracting each
of the decline components from lung function at t1. Each indi-
vidual is assigned a standardised random effect at entry into the
population, which is then scaled according to the variance com-
ponents for each of the age, smoking and asthma-related declines.
Let ai,21 and ai,22 represent random effects from a standard normal
distribution for worker i, for FEV1 and FVC respectively, and let the
subscripts age, sm and asthma refer to age, smoking and asthma.
The annual FEV1 and FVC declines are denoted by DFEVi and DFVCi
respectively and can be expressed as the sum of three components:
DFEVi ¼ DFEVi;age þ DFEVi;sm þ DFEVi;asthma
DFEVi;age ¼ emage;1þai;21sage;1
DFEVi;sm ¼ emsm;1þai;21ssm;1
DFEVi;asthma ¼ emasthma;1þai;21sasthma;1
DFVCi ¼ DFCVi;age þ DFVCi;sm þ DFVCi;asthma
DFVCi;age ¼ emage;2þai;22sage;2
DFVCi;sm ¼ emsm;2þai;22ssm;2
DFVCi;asthma ¼ emasthma;2þai;22sasthma;2
where mage;1 and sage;1 are the mean and standard deviation of the
underlying normal distribution for the age-related FEV1 decline
respectively, msm;2 and ssm;2 are the mean and standard deviation
of the underlying normal distribution for the smoking-related FVC
decline etc.
It is more convenient to specify the variability in lung function in
terms of mean and coefﬁcient of variation (CV) for initial lung func-
tion and for the subsequent annual decline (rather than themean and
standard deviation of the underlying normal distribution), which is
why the model has been developed to accept a user-speciﬁed mean
and CV of the lognormal distribution, which we represent by mean
E. Tan et al. / Respiratory Medicine 109 (2015) 1521e15311528and CV respectively. The mean m and standard deviation s of the
underlying normal distribution can easily be derived as follows:
CV ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
es2  1
p
CV2 þ 1 ¼ es2
Therefore
s ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
log

CV2 þ 1
q
;
and
mean ¼ emþ12s2
therefore
m ¼ logðmeanÞ  1
2
s2:
After simulation year t, the updated FEV1 for the ith individual
is:
FEVi;t ¼ FEVi;t1 þ DFEVi;t
The assumption is made that the random effects for initial FEV1,
initial FVC, FEV1 decline and FVC decline are correlated, and follow
a multivariate normal distribution as follows:
ai ¼
0
BB@
ai1
ai2
ai1
ai2
1
CCA  Nðm;SÞ
m ¼
0
BB@
mi1
mi2
mi1
mi2
1
CCA
S ¼
s211 r12s11s21 r13s11s12 r14s11s22
r12s11s21 s
2
21 r23s21s12 r24s21s22
r13s11s12 r23s21s12 s
2
12 r34s12s22
r14s11s22 r24s21s22 r34s12s22 s
2
22
0
BBB@
1
CCCATable A1
Model parameters and their contribution to the variance of COPD prevalence in male no
Parameter Range
Min
Proportion asthmatic 0.119
Additive asthma adjustment to baseline FEV1 0.486
Addition asthma adjustment to baseline FVC 0.405
Additive asthma adjustment to FEV1 decline 0.00078
Additive asthma adjustment to FVC decline 0
Coefﬁcient of variation for baseline FEV1 0.08
Coefﬁcient of variation for baseline FVC 0.08
Coefﬁcient of variation for age-related FEV1 decline 0.01
Coefﬁcient of variation for age-related FVC decline 0.01
Correlation coefﬁcient: baseline FEV1, FEV1 decline 0
Correlation coefﬁcient: baseline FEV1, baseline FVC 0.7
Correlation coefﬁcient: FEV1 decline, FVC decline 0.4
GOLD II risk ratio, GOLD I 1.26
GOLD III risk ratio, GOLD II 1.69
GOLD IV risk ratio, GOLD III 1.93
FEV1 decline (expressed as proportion of baseline) 0.90This representation allows for correlation in the random effects
through the parameters r12; r13… The correlation coefﬁcients are
model inputs, taking baseline values of r12 ¼ 0:88; r34 ¼ 0.9,
r13 ¼ r14 ¼ r24 ¼ 0.4 (see Table 1).
The change in lung function with age, the variability between
individuals and between smokers and non-smokers can be seen in
Video 1 (in the online supplementary material). The animation
begins in year 1961 with an initial cohort of 20 year olds, and ends
in year 2020 with the same individuals, who by that time are 79
years of age. The blue dots indicate permanent non-smokers (i.e.
those who remain non-smokers between 1961 and 2020); the red
dots indicate smokers. The model attempts to simulate variability
between individuals thus some individuals do not develop COPD
within the simulation timeframe, and the most susceptible in-
dividuals progress quickly to GOLD IV.
Supplementary data related to this article can be found online at
http://dx.doi.org/10.1016/j.rmed.2015.09.011.Sensitivity analysis
Sensitivity analyses can be carried out using a variety of
different approaches. In recent years, the use of Gaussian process
emulators [45] has gained popularity; an emulator is a statistical
representation of a more complex model and can be used as a
surrogate, in situations where runningmany instances of themodel
would be computationally expensive. In the case of the COPD
simulation model, replacing the computationally expensive simu-
lator with the more efﬁcient Gaussian process emulator enables a
global sensitivity analysis to be carried out at signiﬁcantly less
computational expense. In this paper, a variance-based sensitivity
analysis is carried out, whereby the total variance in the output is
apportioned to the sources of variation in the model inputs, thus
enabling identiﬁcation of the most inﬂuential model parameters.
Tables A1 and A2 present the parameter inputs that were
considered in the ﬁrst and second stages of the sensitivity analysis,
along with their limits, and the total effect variance contribution
associated with each parameter. Figures A1 and A2 show the ex-
pected value of COPD prevalence in non-smokers and smokers
respectively at ages 35, 45, 55 and 65, when each input parameter
was varied between its limits and averaged over all the other input
parameters.n-smokers at ages 35, 45 55 and 65.
Total effect variance contribution to COPD prevalence at age
… (%)
Max 35 45 55 65
0.179 0.49 1.24 1.24 1.16
0 7.43 6.64 4.32 1.64
0 3.87 2.90 2.08 1.16
0.0224 3.44 5.69 8.16 3.70
0.0204 8.26 19.21 24.44 17.35
0.18 31.25 29.44 13.87 2.98
0.18 22.85 18.50 8.72 2.45
0.8 1.08 2.54 17.90 47.46
0.8 0.21 5.28 19.06 26.30
0.4 0.35 0.00 0.29 0.24
0.95 40.70 29.14 12.30 2.78
1 0.26 1.17 1.95 3.29
1.77 0.16 0.10 0.00 1.28
3.46 0.09 0.14 1.04 0.00
6.61 2.97 0.49 0.08 0.88
1.10 4.63 6.98 8.97 5.91
Table A2
Model parameters and their contribution to the variance of COPD prevalence in male smokers at ages 35, 45, 55, 65 and 75.
Parameter Range Total effect variance contribution to COPD prevalence at
age … years (%)
Min Max 35 45 55 65
Proportion asthmatic 0.119 0.179 1.05 0.02 0.17 0.35
Additive asthma adjustment to baseline FEV1 (litre) 0.486 0 5.08 3.34 1.62 1.29
Addition asthma adjustment to baseline FVC (litre) 0.405 0 3.19 1.54 1.89 0.56
Additive asthma adjustment to FEV1 decline (litre) 0.00078 0.0224 1.55 2.01 2.89 1.08
Additive asthma adjustment to FVC decline (litre) 0 0.0204 4.17 5.50 5.57 6.20
Coefﬁcient of variation for baseline FEV1 0.08 0.18 22.19 11.09 4.55 1.94
Coefﬁcient of variation for baseline FVC 0.08 0.18 18.01 8.83 3.90 1.46
Coefﬁcient of variation for age-related FEV1 decline 0.01 0.8 0.87 0.44 5.60 16.64
Coefﬁcient of variation for age-related FVC decline 0.01 0.8 0.62 1.36 4.62 7.63
Coefﬁcient of variation for smoking-related FEV1 decline 0.5 1.5 1.15 0.91 3.00 5.42
Coefﬁcient of variation for smoking-related FVC decline 0.5 1.5 0.12 0.44 0.85 1.24
Correlation coefﬁcient: baseline FEV1, FEV1 decline 0 0.7 0.59 0.09 0.00 0.00
Correlation coefﬁcient: baseline FEV1, baseline FVC 0.832 0.935 28.10 10.82 3.97 1.68
Correlation coefﬁcient: FEV1 decline, FVC decline 0.7 1 1.02 0.95 0.48 0.56
GOLD II risk ratio 1.26 1.77 0.07 0.41 0.39 0.16
GOLD III risk ratio 1.69 3.46 0.00 0.00 0.00 0.13
GOLD IV risk ratio 1.93 6.61 0.09 0.28 0.45 0.41
FEV1 decline (expressed as proportion of baseline) 0.90 1.10 0.51 1.33 2.06 1.90
FEV decline in heavy smoker (litre) 0.007 0.018 23.87 46.85 50.65 40.65
FVC decline in heavy smoker (litre) 0.004 0.015 8.44 17.77 21.47 22.53
Risk ratio, ex-smoker 1.15 1.50 0.02 0.34 0.00 0.00
Risk ratio, light smoker 1.57 2.04 0.64 0.70 0.15 0.23
Risk ratio, heavy smoker 2.29 2.97 0.91 0.50 0.03 0.52
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Fig. A1. Sensitivity of the prevalence of COPD in non-smokers aged 35, 45, 55 and 65 years to model parameters.
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Fig. A2. Sensitivity of the prevalence of COPD in smokers aged 35, 45, 55 and 65 years to model parameters.
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